Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.
12,086.70114.9
Stock Analysis, IPO, Mutual Funds, Bonds & More

Johnson & Johnson resumes production of talc in India after regulators find no evidence of asbestos

J&J's talc came under controversy once again in India when Indian drug regulators ordered the testing of the talc to check if it contained cancer causing asbestos.

, ET Bureau|
Feb 28, 2019, 09.03 PM IST
0Comments
Agencies
Johnson-and-Johnson-Agencies
J&J said research, clinical evidence and nearly 40 years of studies by independent medical experts around the world continue to support the safety of cosmetic talc.
MUMBAI: US talc maker Johnson & Johnson (J&J) on Thursday said that it has resumed production of its Johnson’s Baby Powder at plants in Baddi and Mulund, India after Government sanctioned testing reaffirmed that the product does not contain asbestos.

This conclusion by India's drug controller reinforces the findings of decades of independent tests by universities, research labs and government regulators around the world that have consistently found that our talc is safe, J&J said in a statement.

"We stand behind the safety of our talc, which is routinely tested by both suppliers and independent labs to ensure it is free of asbestos. Johnson & Johnson has cooperated fully and openly with global regulators, providing them with all the information they have requested dating back to the 1960s, and has made its cosmetic talc sources and processed talc available to regulators for testing", a J&J spokesperson said in a media statement.

J&J's talc came under controversy once again in India when Indian drug regulators ordered the testing of the talc to check if it contained cancer causing asbestos.

Within baby care market worth Rs4000 crore, J&J controls three-fourth of the baby care market although it is facing growing competition from players including Dabur India and Himalaya Drug Company. Two years ago, Hindustan Unilever launched baby care products under Dove in a market where an estimated 26 million children are born every year.

While the company has lost share to Japanese firm Unicharm and Procter & Gamble in sanitary pads segment, J&J share in both soaps and skin care has fallen 100 basis points to 3% in calendar year 2017 compared to over 4.5% in 2014, as per industry quoting Nielsen data.

J&J said research, clinical evidence and nearly 40 years of studies by independent medical experts around the world continue to support the safety of cosmetic talc.

Also Read

Faulty hip implants by Johnson & Johnson raised in Rajya Sabha

Johnson & Johnson denials of asbestos in baby powder spur criminal probe

Johnson & Johnson pays Rs 25 lakh each to three victims of faulty hip implants

Not all who received Johnson & Johnson hip implants may get damages

Controversies hurt Johnson & Johnson’s sales in India

Comments
Add Your Comments
Commenting feature is disabled in your country/region.
Download The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.

Other useful Links


Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service